VBI Vaccines Inc.

NASDAQ:VBIV   3:59:59 PM EDT
3.05
-0.08 (-2.40%)
4:49:24 PM EDT: $3.05 +0.01 (+0.16%)
Products

VBI Vaccines Announces Initiation Of Enrollment In Adaptive Phase 1/2 Study Of VBI-2902

Published: 03/09/2021 13:22 GMT
VBI Vaccines Inc. (VBIV) - Vbi Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic Covid-19 Vaccine Candidate, Vbi-2902.
Vbi Vaccines Inc - Initiation of Phase 1/2 Study of Pan-coronavirus Vaccine Candidate, Vbi-2901, Anticipated Later in 2021.
Vbi Vaccines Inc - Initial Data From Phase 1 Vbi-2902 Study Expected by End of Q2 2021, Subject to Rate of Enrollment.